渤健公司(Biogen)与Denali Therapeutics Inc. 近日就双方共同研发的、针对早期帕金森病的在研药物Biib122(亦称Dnl151)的IIb期临床试验(Luma研究)提供了最新进展信息。
渤健公司(Biogen)与Denali Therapeutics Inc. 近日就双方共同研发的、针对早期帕金森病的在研药物Biib122(亦称Dnl151)的IIb期临床试验(Luma研究)提供了最新进展信息。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.